The Best Barrier Products for Lichen Sclerosus Mucosal Skin
Most barrier product recommendations for lichen sclerosus treat all skin in the affected area as the same. They are not. The external vulvar skin, the perianal zone, and the outer rim tissue are keratinized skin, structurally similar to skin elsewhere on the body, with a functional stratum corneum and a tolerance for a reasonably wide range of ingredients. The mucosal and mucosa adjacent tissue, the inner labia minora, the vaginal introitus, the clitoral hood internally, the tissue immediately surrounding these areas, is a fundamentally different surface. Thinner, more permeable, more reactive, and significantly less tolerant of the preservative systems, emulsifiers, and botanical actives that are acceptable on keratinized skin.
This distinction matters enormously in LS because the disease predominantly affects precisely the zones where mucosal and mucosa adjacent tissue is most concentrated. Most barrier products, including those most commonly recommended in LS communities, were formulated for keratinized skin. Applying them to mucosal tissue produces a range of outcomes from suboptimal to actively counterproductive, not because the product is bad, but because it was designed for a different surface.
This article covers the two products that are most appropriate for mucosa adjacent LS barrier management: Ceramol Beta Intimo and VEA Lipo 3. It explains their ingredient level biology, what each one is and is not doing, how they compare to each other and to the products most patients are currently using, and how to choose between them based on tissue state and clinical situation.
In this article
- Why mucosal tissue needs different products
- The biology of mucosal barrier disruption in LS
- Ceramol Beta Intimo: full ingredient breakdown and mechanism
- VEA Lipo 3: full ingredient breakdown and mechanism
- How Ceramol and VEA Lipo 3 compare to products you may already be using
- How to choose between them by tissue state
- How to transition from your current product
- Layering with other products in the routine
- Frequently asked questions
Why mucosal tissue needs different products
The mucosal epithelium is structurally different from keratinized epidermis in several ways that directly determine which barrier products are appropriate.
Mucosal tissue lacks the thick stratum corneum that gives keratinized skin much of its barrier function. It is thinner, more permeable, and relies on a mucus layer and tight junction proteins rather than a lipid matrix as its primary barrier mechanism. This means topical products penetrate more deeply on mucosal tissue than on keratinized skin, reaching layers and nerve endings that would not be exposed on intact external skin.
On LS affected mucosal tissue, this penetration problem is compounded by the disrupted barrier that characterizes the disease even during apparently stable periods. The depleted lipid matrix, the increased transepidermal water loss, and the structurally altered keratinocyte architecture of LS affected tissue lower the threshold at which any ingredient can cause irritation. Preservatives, emulsifiers, and botanical actives that are well tolerated on normal keratinized skin reach immune active layers on LS mucosal tissue that they were never intended to contact.
The practical consequence is consistent: patients apply products that work fine on external skin to mucosa-adjacent tissue, experience burning or irritation, and interpret this as a flare or a product allergy. In many cases it is neither. It is a tissue state mismatch. The correct product for that tissue zone simply was not used.
Three criteria determine whether a product is appropriate for mucosal or mucosa adjacent LS tissue. The emulsifier system matters because products containing PEG based emulsifiers, ethoxylated compounds, or surfactant adjacent emulsifiers carry barrier disruption potential on mucosal tissue. Polyglyceryl emulsifiers are the mucosal grade standard. The preservative system matters because phenoxyethanol, methylisothiazolinone, formaldehyde releasing preservatives, and parabens are among the most common contact sensitizers on compromised mucosal tissue, and anhydrous products require no preservatives at all. The active ingredient load matters because botanical extracts, essential oils, high concentrations of acids, and many synthetic actives penetrate mucosal tissue more deeply than intended, and products designed specifically for intimate mucosal use manage this with a different active ingredient selection.
Ceramol Beta Intimo and VEA Lipo 3 both meet these criteria. Most other commonly recommended LS barrier products do not.
The biology of mucosal barrier disruption in LS
Understanding why mucosal barrier disruption is so persistent in LS explains why the product choices covered here matter more than they might appear to.
LS produces structural changes in the affected tissue that persist even during clinically stable periods. The lipid matrix is depleted. Ceramide content is reduced. Transepidermal water loss is elevated. These changes are present even when the tissue looks relatively normal and symptoms are quiet. The tissue is not the same as unaffected skin. It has a lower activation threshold and a reduced margin for mechanical and chemical stress.
When the mucosal barrier is disrupted, ordinary daily activities generate micro injuries that reach the immune reactive layers beneath. Each micro injury activates local immune cells, which release cytokines that amplify inflammation, which further disrupts the barrier. This is the barrier inflammation loop, self sustaining, and continuing to generate immune activation for as long as the barrier remains insufficiently recovered to prevent ordinary stimuli from reaching immune tissue.
Barrier support products interrupt this loop from the mechanical side by reducing friction, by replacing the structural lipid components that the barrier cannot maintain on its own, and in the case of Ceramol Beta Intimo, by providing active ingredients that address the neuroimmune and inflammatory processes operating within the loop.
The goal of barrier management in LS is not comfort. It is immune environment control, reducing the daily micro injury input that sustains loop activity between courses of anti inflammatory treatment.
Ceramol Beta Intimo: full ingredient breakdown and mechanism
INCI: Aqua, Dicaprylyl Carbonate, Glycerin, Caprylic/Capric Triglyceride, Polyglyceryl-2 Dipolyhydroxystearate, Polyglyceryl-3 Diisostearate, Butyrospermum Parkii Butter, Dimethicone, Squalane, Ceramide 3, Cholesterol, Stearic Acid, N-Isopropyl Palmitoylamide, Stearyl Glycyrrhetinate, Piroctone Olamine, Allantoin, Bisabolol, Hydrogenated Palm Oil, Hydrogenated Rapeseed Oil, Magnesium Sulfate, O-Cymen-5-Ol, Undecylenoyl Glycine.
Manufactured by Unifarco (Italy), Ceramol Beta Intimo was specifically designed for intimate mucosal use. That design intent is visible in every ingredient decision.
The emulsifier system
Polyglyceryl-2 Dipolyhydroxystearate and Polyglyceryl-3 Diisostearate.
Polyglyceryl emulsifiers have no PEG chains and no ethoxylation. They are the highest standard available for intimate mucosal formulations. Standard emulsifiers used in most skincare products, cetearyl alcohol, polysorbate-20, PEG derivatives, have varying degrees of barrier disruption potential on mucosal surfaces. Polyglyceryl systems avoid this entirely. For a patient applying this product daily to mucosa adjacent tissue, the emulsifier choice is not a minor detail. It is the difference between a product that supports the barrier and one that contributes to its ongoing depletion.
The oil base
Dicaprylyl Carbonate, Caprylic/Capric Triglyceride (MCT), and Squalane.
All three are chemically inert, with zero polyunsaturated fatty acid (PUFA) content and zero oxidation risk. This matters because high PUFA oils, rosehip, hemp seed, flaxseed, grape seed, oxidize on the skin surface, producing pro inflammatory compounds including 4-hydroxynonenal and malondialdehyde that activate the same NF-kB pathways involved in LS inflammation. On LS-affected tissue with its disrupted barrier and sensitized immune environment, these oxidation products find a surface primed to respond to them. Ceramol uses none of these oils. The base is lighter than mineral oil or petrolatum based products, appropriate for daily mucosa adjacent wear without the occlusive heaviness that can feel uncomfortable in warm conditions.
The lipid matrix system
Ceramide 3, Cholesterol, Stearic Acid.
This is the ceramide cholesterol fatty acid trio required for structurally complete barrier lipid matrix restoration. The stratum corneum's lipid matrix is organized in lamellar layers composed of these three components in specific ratios. Products containing ceramides alone, without cholesterol and free fatty acids, cannot complete the structural repair that the matrix requires. All three components are present in Ceramol, making it more mechanistically complete than most single ceramide barrier products.
The PEA analogue: neuroimmune and mast cell calming
N-Isopropyl Palmitoylamide.
This is the ingredient that most distinguishes Ceramol from all other commercially available barrier products for LS mucosal use. It is a structural analogue of palmitoylethanolamide (PEA), a naturally occurring fatty acid amide produced endogenously in skin and neural tissue.
PEA activates PPAR-alpha receptors, which are expressed in keratinocytes, mast cells, and sensory neurons. PPAR-alpha activation downregulates mast cell degranulation, reduces the release of inflammatory mediators including histamine and tryptase, and directly inhibits the production of IL-31, the primary itch cytokine in LS. Simultaneously, PEA calms the hypersensitivity of C-fiber nerve endings, the peripheral nerve fibers responsible for the burning, itch, and pain that characterize LS symptoms even when inflammation appears controlled.
For LS patients, this mechanism addresses the neuroimmune itch loop directly. This loop, sensitized nerves firing at lower thresholds, generating itch disproportionate to the inflammatory stimulus, with scratching feeding back into the barrier and inflammation loops, is one of the five feedback loops that sustain the disease. The IL-31 signaling and C-fiber hypersensitivity that drive this loop do not resolve automatically when cytokine levels are reduced by steroid treatment. A product that actively calms these pathways in the daily maintenance routine is addressing a component of LS biology that pharmaceutical treatment typically does not reach between courses.
The glycyrrhetic acid layer: anti inflammatory without steroids
Stearyl Glycyrrhetinate.
Glycyrrhetic acid is the primary bioactive compound in licorice root. Esterified as stearyl glycyrrhetinate for topical delivery, it provides genuine anti inflammatory activity via inhibition of 11beta hydroxysteroid dehydrogenase (11beta-HSD), the enzyme that inactivates cortisol in peripheral tissue. By inhibiting this enzyme, glycyrrhetic acid increases local cortisol activity without introducing exogenous steroid. The result is a cortisol like anti inflammatory mechanism that suppresses local inflammatory cytokine production without the skin thinning atrophic effects associated with topical corticosteroid use.
This makes Stearyl Glycyrrhetinate one of the most mechanistically interesting non pharmaceutical topical anti inflammatory actives available, and its presence in a daily maintenance product means Ceramol provides ongoing low level inflammatory suppression between courses of pharmaceutical treatment, precisely the window where the inflammation loop tends to reestablish through immune memory activation.
The antimicrobial balance layer
Piroctone Olamine and Undecylenoyl Glycine.
In LS, the altered local microbiome, with reduced Lactobacillus dominance, disrupted pH, and increased barrier permeability, creates conditions where opportunistic yeast populations, particularly Candida, can expand with minimal provocation. Even a mild Candida population imbalance on LS tissue produces burning and itch that is genuinely indistinguishable from LS immune activation. Managing this background ecological vulnerability is a practical clinical priority for many LS patients.
Piroctone Olamine has broad antifungal activity (it inhibits ergosterol synthesis in fungal cell membranes) and is among the best tolerated antifungal actives for mucosal use. Undecylenoyl Glycine provides complementary antimicrobial and antifungal activity. Together, they provide daily microbiome compatible preventive balance without the pharmacological load of a dedicated antifungal treatment.
Tolerability actives
Bisabolol (isolated, not chamomile oil, so no allergen risk) reduces NF-kB activity modestly and calms irritation with good mucosa compatibility. Allantoin promotes keratinocyte proliferation and skin healing. O-Cymen-5-Ol is the preservative, and it is generally well tolerated on mucosa at the concentrations used.
Best phase fit and appropriate use
Phases 3 and 4, meaning stable, closed, non erosive mucosa adjacent tissue. Ceramol is not appropriate on open, erosive, or actively inflamed Phase 1 or 2 tissue. The active ingredient complexity that makes it so effective in stable phases makes it inappropriate when the barrier is broken and penetration depth is uncontrolled. On disrupted tissue, the correct products are petrolatum or VEA Lipo 3.
Best situations: daily mucosa adjacent maintenance during remission, between flare barrier protection with active anti inflammatory and neuroimmune support, patients with a pattern of disproportionate burning or itch on tissue that appears relatively stable (this is where the neuroimmune loop calming activity of the PEA analogue is most relevant), and patients with a history of recurrent Candida overlap who need daily barrier support with built in antifungal balance.
VEA Lipo 3: full ingredient breakdown and mechanism
INCI: Butyrospermum Parkii Butter, Tocopheryl Acetate, Caprylic/Capric Triglyceride, Palmitic/Stearic Triglyceride, Hydrogenated Castor Oil, Ceramide NP, Phytosterols.
VEA Lipo 3 is a completely anhydrous product, meaning no water, which means no emulsifiers and no preservatives. Seven ingredients total. This is its defining clinical advantage: the absolute minimum chemical complexity compatible with genuine barrier lipid repair.
The anhydrous advantage
No water means no need for preservatives. No preservatives means zero preservative irritation risk. On hypersensitive LS mucosal tissue, where methylisothiazolinone, phenoxyethanol, and parabens are among the most consistent contact sensitizers, the complete elimination of this risk category is clinically significant. It also means no emulsifiers are needed, removing another category of potential mucosal irritation entirely.
For patients who react to almost everything, VEA Lipo 3 removes two of the three most common causes of product reactions on LS mucosal tissue (preservatives and emulsifiers) by structural design, not by selecting "safer" versions of these ingredients.
The lipid base
Butyrospermum Parkii Butter (shea), Caprylic/Capric Triglyceride (MCT), and Palmitic/Stearic Triglyceride.
Shea butter provides a blend of stearic and oleic fatty acids alongside phytosterols, triterpene alcohols, and tocopherols naturally occurring in the butter. MCT is fully saturated, zero PUFA, zero oxidation risk, and provides excellent friction reduction with a lighter texture than petrolatum. Palmitic/Stearic Triglyceride adds saturated fatty acids that contribute to the barrier lipid matrix. Hydrogenated Castor Oil contributes to the semi solid texture and provides additional occlusion. All components have low to zero PUFA content. There is no oxidative risk in this formula.
Ceramide NP
Ceramide NP (also known as Ceramide 2) is a skin-identical ceramide, the type naturally present in the stratum corneum's lipid matrix and typically depleted in LS affected tissue. Topical supplementation with skin identical ceramides provides the structural lipid components the barrier needs to restore its sealing capacity. One ceramide type versus Ceramol's full ceramide cholesterol fatty acid trio makes VEA Lipo 3 less structurally complete for barrier lipid matrix repair. But for sensitive or transitional tissue states where simplicity is the priority, one well chosen ceramide in an anhydrous preservative free base is more useful than a more complete formula that carries preservative or emulsifier risk.
Phytosterols
Phytosterols are plant derived sterol compounds structurally similar to cholesterol. They support membrane structure and have mild anti inflammatory properties via modulation of inflammatory signaling pathways. They partially compensate for the absence of cholesterol in the formula, not as completely as dedicated cholesterol would, but meaningfully enough to make VEA Lipo 3 a genuine barrier support product rather than just a surface occlusive.
Tocopheryl Acetate
Vitamin E in its stable ester form. It provides antioxidant protection at the skin surface, protecting the barrier lipids from oxidative damage. Well tolerated across tissue states.
What VEA Lipo 3 is and is not
VEA Lipo 3 is a high quality anhydrous barrier and lipid support product with a genuine ceramide and phytosterol component. It is not as functionally complete as Ceramol Beta Intimo. It lacks the PEA analogue neuroimmune calming layer, the glycyrrhetic acid anti inflammatory layer, the full ceramide cholesterol fatty acid trio, and the antifungal balance layer. But it occupies a specific and important clinical space between petrolatum (pure occlusion, no repair) and Ceramol (full functional activity, requires stable closed tissue). It is the right product when the tissue needs more than petrolatum can provide but is not yet stable enough to tolerate Ceramol's active ingredient load.
Best phase fit and appropriate use
Phases 2 through 4, particularly Phase 2 transition and Phase 3 or 4 in patients who need maximum formula simplicity or who have not yet trialed Ceramol.
Best situations: acute to transition phase protection on mucosal or mucosa adjacent tissue, overnight application when an anhydrous preservative free protective layer is wanted without the texture of petrolatum, maximum sensitivity periods when the tissue is reacting to multiple products, first product to trial for patients with a history of reacting to everything (the seven-ingredient formula eliminates most sources of contact reaction by design), bridge between petrolatum and Ceramol during the post flare recovery phase, and alternative to Ceramol in hot or humid conditions where a lighter anhydrous texture is preferred.
How Ceramol and VEA Lipo 3 compare to products you may already be using
vs Petrolatum
Petrolatum provides pure occlusion, no structural lipid components, no active ingredients, zero irritation risk. It is the correct product for open or erosive tissue of any type, as a pre friction barrier, and as a base layer before stinging products. VEA Lipo 3 and Ceramol are not replacements for petrolatum in these situations. They are upgrades for stable or recovering tissue that needs more than occlusion alone.
vs CeraVe Healing Ointment
CeraVe Healing Ointment contains three ceramide types (NP, AP, EOP), cholesterol, phytosphingosine, and hyaluronic acid in a petrolatum base. It has good mucosa safety (approximately 8.5/10 for the EU version with benzoic acid preservative). For external skin and mucosa adjacent use in patients who tolerate formulated products well, CeraVe is a strong option for barrier lipid repair. Its limitation compared to Ceramol is the absence of neuroimmune calming activity, anti inflammatory activity beyond the ceramide lipid support, and antifungal balance. Compared to VEA Lipo 3, it contains preservatives and emulsifiers which may cause irritation in very sensitive patients.
The practical hierarchy: petrolatum for acute or open tissue, VEA Lipo 3 for sensitive transitional states, CeraVe Healing Ointment for stable tissue when simplicity is preferred over Ceramol's fuller activity, Ceramol Beta Intimo for stable mucosa adjacent maintenance when comprehensive barrier and neuroimmune support is the goal.
vs Cicaplast Baume B5+ (La Roche-Posay)
Cicaplast contains panthenol, madecassoside (centella), niacinamide, and dimethicone. It is an excellent product for external keratinized skin in phases 2 through 4, particularly for its madecassoside antifibrotic bias on external rim and border zones. It is not appropriate for mucosal or mucosa adjacent tissue. Its emulsifier and preservative system are formulated for external skin, and its mucosa safety is approximately 6/10. For the tissue zones where most LS patients need the most support, Cicaplast is not the right tool, even though it is well formulated for what it is designed to do.
vs Cicalfate+ (Avène)
Cicalfate+ provides a sucralfate scaffold for external skin repair during the closing phase, a function no other product in this comparison replicates. It is specifically for external keratinized skin only. Mucosa safety is approximately 3/10. Patients using Cicalfate+ on mucosal or mucosa adjacent tissue are applying an external skin product to the wrong tissue zone.
vs Vaseline with added oils or DIY mixtures
Mixing oils into petrolatum or combining multiple natural products creates an uninterpretable clinical picture. If a reaction occurs, the cause cannot be identified. If high PUFA oils are used (rosehip, hemp, flaxseed), oxidation products are introduced to already sensitized tissue. VEA Lipo 3 and Ceramol eliminate both problems: they are tested, stable formulations with known ingredient profiles and no PUFA oxidation risk.
How to choose between Ceramol and VEA Lipo 3
The decision between Ceramol Beta Intimo and VEA Lipo 3 for any given patient and situation comes down to three questions.
Is the tissue open, fragile, or in an uncertain transitional state? If yes, use VEA Lipo 3. Anhydrous, preservative free, seven ingredients, maximum simplicity. The active ingredient complexity in Ceramol is not appropriate when penetration depth is uncontrolled.
Is the patient reacting to most products, or has never found a mucosal safe barrier that works? If yes, start with VEA Lipo 3. The complete absence of preservatives and emulsifiers removes the two most common causes of contact reactions on LS mucosal tissue. Once tolerated, trial Ceramol.
Is the tissue stable and closed, and is the dominant remaining concern neuroimmune itch, low grade inflammation, or Candida vulnerability? If yes, use Ceramol Beta Intimo. The PEA analogue addresses neuroimmune itch that pharmaceutical treatment does not reach. The glycyrrhetic acid provides ongoing low level anti inflammatory support. The antifungal balance addresses Candida vulnerability.
Clinical situationProductOpen or erosive tissue, any zonePetrolatum (not Ceramol or VEA Lipo 3)Transitional, closing but uncertainVEA Lipo 3History of reacting to everythingVEA Lipo 3 firstStable, closed, neuroimmune itch dominantCeramol Beta IntimoStable, closed, Candida patternCeramol Beta IntimoStable, closed, maximum simplicity preferredVEA Lipo 3Stable, closed, comprehensive maintenance goalCeramol Beta IntimoWarm climate, lighter texture neededVEA Lipo 3Overnight protective layer, any stable phaseEither, VEA Lipo 3 for simplicity, Ceramol for fuller activity
How to transition from your current product
If you are currently using Cicaplast or Cicalfate+ on mucosal or mucosa adjacent tissue, the transition is straightforward but should be done one step at a time.
Stop the current product on mucosal or mucosa adjacent zones first. Continue it on external keratinized skin if it is working there. If the tissue is in any uncertain or transitional state, start with petrolatum for one week to establish a clean baseline and observe the tissue response. Then introduce VEA Lipo 3 once the tissue is tolerating petrolatum without reaction. Apply once daily and observe for three to five days before increasing frequency. Once VEA Lipo 3 is well tolerated, introduce Ceramol Beta Intimo if the tissue state is stable. Start with one application daily alongside VEA Lipo 3, and transition to Ceramol as the primary product over one to two weeks.
Never introduce both VEA Lipo 3 and Ceramol simultaneously. If a reaction occurs, you need to know which product caused it.
Layering with other products in the routine
Ceramol Beta Intimo and VEA Lipo 3 are designed to work alongside other products in a layered routine, not to replace every other product.
A stable maintenance routine might look like this. In the morning, apply Ceramol Beta Intimo on mucosa adjacent tissue after cleansing and fully drying. Thin application. This is the daily neuroimmune support, anti inflammatory, and lipid repair layer. Before friction activities (exercise, sex, prolonged sitting), apply petrolatum over the Ceramol layer on fully dry skin for maximum occlusion before mechanical stress. In the evening, repeat Ceramol Beta Intimo, or use VEA Lipo 3 if a simpler anhydrous option is preferred overnight. On external keratinized skin in the evening, Cicaplast Baume B5+ is appropriate on external rim and border zones where its madecassoside antifibrotic activity is relevant. This does not overlap with Ceramol's mucosal zone. The morning after overnight clobetasol use, apply Ceramol Beta Intimo or CeraVe Healing Ointment on the mucosa adjacent zone as a buffer layer.
The principle is one active layer per zone per application. Protection and repair matched to the tissue zone. No simultaneous introduction of new products.
Frequently asked questions
Is Ceramol Beta Intimo safe to use every day long term?
Yes. The formula is specifically designed for daily intimate mucosal use. No ingredient in the formula has known toxicity concerns with daily topical use. The preservative (O-Cymen-5-Ol) is selected for mucosal compatibility. The antifungal components are at concentrations appropriate for daily use rather than pharmacological treatment. Long term daily use is the intended application pattern.
Can I use Ceramol Beta Intimo during a flare?
Not on open or erosive tissue. During an active flare with any surface disruption, use petrolatum or VEA Lipo 3. Ceramol's active ingredient complexity requires intact barrier tissue to function as intended. On disrupted tissue, the same ingredients that provide targeted anti inflammatory and neuroimmune calming activity on intact tissue can cause irritation because they reach tissue layers they were not intended to contact. Transition to Ceramol after the surface has genuinely closed and the tissue is tolerating product contact without stinging.
What is the difference between VEA Lipogel and VEA Lipo 3?
VEA Lipogel (the original VEA product) is a silicone vitamin E gel. It provides friction reduction and surface protection but no barrier lipid repair, it has no ceramide and no phytosterol. VEA Lipo 3 adds Ceramide NP and phytosterols to a shea, MCT, and palmitic stearic triglyceride base, giving it genuine barrier lipid support capacity. For LS mucosal adjacent use, Lipo 3 is substantially more appropriate than the original Lipogel.
Can I use both Ceramol and VEA Lipo 3 in the same routine?
Yes, but at different times rather than layered simultaneously. VEA Lipo 3 works well as an overnight product when a simpler anhydrous formula is preferred, while Ceramol is used in the morning or afternoon. Or VEA Lipo 3 during transitional periods and Ceramol during stable periods. Using them at different times of day is appropriate. Mixing them together or applying one immediately over the other adds complexity without clear benefit.
Where can I buy Ceramol Beta Intimo outside Italy?
Ceramol Beta Intimo is manufactured by Unifarco in the Veneto region of Italy. It is available through Italian pharmacies and online Italian pharmacy retailers that ship internationally. It is not widely distributed outside Italy and Italy adjacent markets. When purchasing online, verify that you are buying from a registered pharmacy rather than a third party reseller to ensure product authenticity and appropriate storage conditions.
My clinician has never heard of Ceramol Beta Intimo. Should I still use it?
Ceramol Beta Intimo is a cosmetic medical device, not a pharmaceutical. Clinicians are not expected to know every formulated barrier product on the market. The relevant clinical conversation is about barrier support in LS management, a topic your clinician should be able to engage with. You can describe the product's ingredient profile and ask whether any of the components raise concerns given your specific clinical history. The PEA analogue and glycyrrhetic acid components are pharmacologically safe at topical cosmetic concentrations and neither raises concerns that would typically affect a clinician's recommendation to use or avoid a barrier product.
Can men with LS use these products?
Yes. The formulation principles that make Ceramol Beta Intimo and VEA Lipo 3 appropriate for female genital mucosal tissue apply equally to male genital LS. The glans, inner foreskin, and urethral meatus are mucosal or mucosa adjacent tissue with the same structural characteristics and the same tolerability requirements as female mucosal tissue. The "Beta Intimo" designation refers to intimate use, not exclusively female use.
Related: Vaseline, Cicalfate, or Cicaplast? How Barrier Products Actually Work in Lichen Sclerosus
Related: Sex and Lichen Sclerosus: Friction, Tissue Biology, and How to Actually Protect the Skin
Content sourced from: Lichen Sclerosus Decoded, A New Way to Understand and Manage Lichen Sclerosus. For informational purposes only. This article does not constitute medical advice. Please consult a qualified healthcare provider for diagnosis and treatment.